MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. GOOGL
2. NOW
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. CART
10. KLAC

Go back to MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Stifel on MacroGenics (MGNX): 'incrementally more positive', 'We remain buyers into the next “by May 31” clinical update'

April 4, 2024 4:40 AM EDT

Stifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on MacroGenics (NASDAQ: MGNX).

The analyst comments "Were incrementally more positive on MGNX shares following managements disclosure of vobra-duo safety/tolerability data from the P2 TAMARACK trial contained within an... More